|
|
Post by patience1 on Nov 19, 2024 12:16:18 GMT -5
PFE is going through a rough time right now as the share price confirms. PFE could use a new product that can help gain public trust again for adults and children. With the vaccines debacle hanging over their(PFE) heads and RFK looking to assure proper testing for all vaccines and proper testing transparency MNKD could be very helpful to Pfizer. Afrezza has been tested on Adults now for a long time and a great safety record and with PED approval on the horizon the top management of PFE should reconsider inhaled insulin. It could be a big Win/Win/Win for all three PFE, MNKD and anyone dealing with Diabetes.
|
|
|
|
Post by cjm18 on Nov 19, 2024 13:01:33 GMT -5
What Vaccine debacle? The entire sector went down. Xbi and IBb.
|
|
|
|
Post by prcgorman2 on Nov 19, 2024 14:08:15 GMT -5
PFE is going through a rough time right now as the share price confirms. PFE could use a new product that can help gain public trust again for adults and children. With the vaccines debacle hanging over their(PFE) heads and RFK looking to assure proper testing for all vaccines and proper testing transparency MNKD could be very helpful to Pfizer. Afrezza has been tested on Adults now for a long time and a great safety record and with PED approval on the horizon the top management of PFE should reconsider inhaled insulin. It could be a big Win/Win/Win for all three PFE, MNKD and anyone dealing with Diabetes. Pfizer developed an inhalable insulin once before so they've demonstrated a willingness to try selling inhalable insulin (at least once).
Exubera (sp) was a big fail though. It was an RAA insulin and the performance profile wasn't anywhere close to Afrezza.
The Pfizer executive who oversaw the Exubera failure was Oliver Brandicoot [sic] who soon after became CEO of Sanofi and was the key executive responsible for cancelling the $1B+ world wide marketing agreement with MannKind for Afrezza. That debacle, as much as anything else, is the reason Afrezza has been for sale for 10 years with not much to show for it. MannKind very nearly went bankrupt (but for Afrezza ironically enough).
Would Pfizer consider marketing someone else's inhalable insulin? One good thing is Afrezza has the cool little dreamboat whistle instead of the big ass Exubera bong.
I have my doubts though I kind of like the idea. At least this time if Big BP dropped the ball on Afrezza (again), MannKind wouldn't be a one trick pony with a busted front leg.
|
|
|
|
Post by mikesmilitaria on Nov 20, 2024 15:39:49 GMT -5
That company's core business is toxins which implies Afrezza is not a fit.
|
|
|
|
Post by patience1 on Nov 20, 2024 18:22:49 GMT -5
Well said Mike but I was hoping after a thorough house cleaning things could be different.
|
|
|
|
Post by sayhey24 on Nov 21, 2024 8:26:17 GMT -5
Albert Bourla knows Mike. I don't know if Mike ever reached out to him on PFE's failed oral GLP1 developments but they are still moving forward with Danuglipron. I think it would be in PFE's best interest to throw $20M at a TS glp-1 pilot.
|
|
|
|
Post by prcgorman2 on Nov 21, 2024 9:51:06 GMT -5
I forgot. What is the advantage gained by inhaling GLP-1?
|
|
|
|
Post by porkini on Nov 21, 2024 10:01:28 GMT -5
^ Side effects, I think.
|
|
|
|
Post by sayhey24 on Nov 21, 2024 11:52:02 GMT -5
I forgot. What is the advantage gained by inhaling GLP-1? For starters - nausea and vomiting and pancreatitis. IMO, a small daily dose via technosphere could provide an option for "obesity maintenance" after the heavy lifting of wegovy is done. From seventeen years ago - "We believe that MKC253 represents a novel approach to the use of GLP-1 as a prandial therapy for diabetes either alone, or in combination with prandial insulin. In addition, if we are able to demonstrate the same weight reduction or satiety effects seen with long-acting analogues of native GLP, MKC253 may have therapeutic potential in obesity" www.diabetesincontrol.com/positive-results-for-inhaled-glp-1-cpd/ |
|
